

Minimizing the “Aggravation” of Platelet Aggregation: The Need for Improved Assessments of Platelet Function

David Varon¹

¹Coagulation Unit, Tel Aviv Medical Center, Tel Aviv, Israel

Thromb Haemost 2019;119:1031–1032.

Address for correspondence David Varon, MD, Coagulation Unit, Tel Aviv Medical Center, Tel Aviv, Israel (e-mail: dvaron@hadassah.org.il).

Light transmission aggregometry (LTA) is the “gold standard” assay for studying platelet function, yet its standardization in the clinical laboratories is challenging.

In this volume of *Thrombosis and Haemostasis*, the THROMKID-Plus Group presents a survey among laboratories from Germany and Austria.¹ They studied five agonists following the Scientific and Standardization Committee/International Society on Thrombosis and Haemostasis recommendations including three different sets, including one simulating a healthy control and other two simulating platelet disorders. Fifteen expert laboratories in Germany and Austria studied platelet function using the above agonists applying LTA. Laboratory-internal agonists were tested as well. The results revealed consistent data regarding the maximum percentage of aggregation and identified the diagnosis of the simulated platelet function disorders. However, significant variability in laboratory-internal agonists including reagent type, concentrations, and pathological cut-off values was observed.

The authors concluded that centrally shipment of standardized agonists may be used for interlaboratory quality assurance of LTA, and yet there is a need for standardization of agonist reagents and their concentration as well as for definition of reference ranges.

Platelet function testing presents several limitations including the need for a fresh blood sample, the need for a gentle handling of the sample due to the very high sensitivity of platelets to ambient conditions (temperature, tilting of the tube), and many others. That may explain the inconsistent results even with the same patient’s blood sample. Moreover, different methods and devices which are in use at the clinical laboratories may yield different results.

One major obstacle in achieving a “common denominator” basis in this field is the different methods which are used, including LTA, impedance aggregometry, and flow analysis of platelet’s expression of activation markers.

The above study together with different societies’ recommendations is promoting our ability to apply LTA as a gold standard test for platelet function abnormalities as well as the response to different platelet’s antagonists.^{2–4} Despite the long time since its development,⁵ LTA probably remains the best assay for these studies, but due to its inter- and intraoperator dependence, there is a need for standardization of all the components, including reagents, blood drawing, procedure’s protocol, etc.

Recently, several devices were developed in an effort to allow platelet function testing at the “point-of-care” environment, employing automated approach, including the “Verify-Now,”⁶ the PFA 100,⁷ Multiplate,⁸ as well as the thromboelastography devices.⁹ These methods are testing platelet function in the acute care setting yielding a general impression (usually a “yes-no” output) but not necessarily a more detailed evaluation of platelet function, thus lacking the flexibility of the LTA as a more diverse system for different applications. Assessments using flow cytometry are also limited by the lack of inter- and intra-assay reproducibility, or lower limits of detection. Perhaps we should even consider scrutiny of assay validation studies that include looking at diurnal variation, exercise, time since sample was taken or processed, body weight, etc., as all these aspects may affect the data when assessing a “labile” parameter such as platelet activation.^{10,11} This is needed given the interest into platelet indices in the clinical setting, especially in relation to interventions and decision-making for antiplatelet drugs use.^{12–17} As new platelet indices and protocols are developed and proposed as biomarkers of platelet function,^{18–20} clear assay validation and reproducibility data are needed.

The paper from the THROMKID-Plus Group¹ contributes to the standardization of reagent used with LTA yet there remains a need for further standardizing other assessments of platelet function as well. Things can only get better.

received
May 28, 2019
accepted
May 28, 2019

© 2019 Georg Thieme Verlag KG
Stuttgart · New York

DOI <https://doi.org/10.1055/s-0039-1692643>.
ISSN 0340-6245.

Conflict of Interest

None declared.

References

- 1 Althaus K, Zieger B, Bakchou T, Jurk K. Standardization of light transmission aggregometry for diagnosis of platelet disorders: an inter-laboratory external quality assessment. *Thromb Haemost* 2019;119(07):1154–1161
- 2 Harrison P, Mackie I, Mumford A, et al; British Committee for Standards in Haematology. Guidelines for the laboratory investigation of heritable disorders of platelet function. *Br J Haematol* 2011;155(01):30–44
- 3 Gresele P, Harrison P, Bury L, et al. Diagnosis of suspected inherited platelet function disorders: results of a worldwide survey. *J Thromb Haemost* 2014;12(09):1562–1569
- 4 Gresele P; Subcommittee on Platelet Physiology of the International Society on Thrombosis and Hemostasis. Diagnosis of inherited platelet function disorders: guidance from the SSC of the ISTH. *J Thromb Haemost* 2015;13(02):314–322
- 5 Born GV. Aggregation of blood platelets by adenosine diphosphate and its reversal. *Nature* 1962;194:927–929
- 6 Rinaldi MJ, Gohs FX, Kirtane AJ, et al. Impact of point-of-care platelet function testing among patients with and without acute coronary syndromes undergoing percutaneous coronary intervention with drug-eluting stents (from the ADAPT-DES Study). *Am J Cardiol* 2019;123(04):549–557
- 7 Dovlatova N, Heptinstall S. Platelet aggregation measured by single-platelet counting and using PFA-100 devices. *Platelets* 2018;29(07):656–661
- 8 Opheim EN, Apelseth TO, Stanworth SJ, Eide GE, Hervig T. Multiple electrode aggregometry and thromboelastography in thrombocytopenic patients with haematological malignancies. *Blood Transfus* 2018. Doi: 10.2450/2018.0140-18
- 9 Zhou H, Chen L, He H. Intraoperative and postoperative effects of TEG-guided platelet transfusion on antiplatelet drug-related intracerebral hemorrhage patients. *Exp Ther Med* 2019;17(03):2263–2267
- 10 Freynhofer MK, Hein-Rothweiler R, Haller PM, et al. Diurnal variability of on-treatment platelet reactivity in clopidogrel versus prasugrel treated acute coronary syndrome patients: a pre-specified TROPICAL-ACS sub-study. *Thromb Haemost* 2019;119(04):660–667
- 11 Elaïb Z, Lopez JJ, Coupaye M, et al. Platelet functions are decreased in obesity and restored after weight loss: evidence for a role of the SERCA3-dependent ADP secretion pathway. *Thromb Haemost* 2019;119(03):384–396
- 12 Gross L, Jochheim D, Nitschke T, et al. Platelet reactivity and early outcomes after transfemoral aortic valve implantation. *Thromb Haemost* 2018;118(10):1832–1838
- 13 Angiolillo DJ. Platelet function or genetic testing for guiding de-escalation of anti-platelet therapy: the jury is still out. *Thromb Haemost* 2018;118(09):1509–1511
- 14 Gross L, Trenk D, Jacobshagen C, et al. Genotype-phenotype association and impact on outcomes following guided de-escalation of anti-platelet treatment in acute coronary syndrome patients: the TROPICAL-ACS Genotyping substudy. *Thromb Haemost* 2018;118(09):1656–1667
- 15 Alexopoulos D, Xenogiannis I, Vlachakis P, Tantry U, Gurbel PA. Peri-procedural platelet reactivity in percutaneous coronary intervention. *Thromb Haemost* 2018;118(07):1131–1140
- 16 Alemanno L, Massimi I, Klaus V, et al. Impact of multidrug resistance protein-4 inhibitors on modulating platelet function and high on-aspirin treatment platelet reactivity. *Thromb Haemost* 2018;118(03):490–501
- 17 de Carvalho LP, Fong A, Troughton R, et al. Prognostic implications of dual platelet reactivity testing in acute coronary syndrome. *Thromb Haemost* 2018;118(02):415–426
- 18 Zheng YY, Wu TT, Chen Y, et al. Gamma-glutamyl transferase-to-platelet ratio as a novel predictor of long-term adverse outcomes in patients after undergoing percutaneous coronary intervention: a retrospective cohort study. *Thromb Haemost* 2019;119(06):1021–1030
- 19 Badimon L. Monocyte-platelet complexes in myocardial infarction: sub-sets and platelet-derived microvesicles matter. *Thromb Haemost* 2018;118(11):1854–1855
- 20 Rauzi F, Smyth E, Emerson M. Refinement of mouse protocols for the study of platelet thromboembolic responses in vivo. *Thromb Haemost* 2017;117(12):2283–2290